Figure 6.

In vivo effects of GB4-BPL@siCXCR2/pPTEN on Enz resistance in EnzR BmCRPC model. (A) Scheme of tumor inoculation, surgical castration and administration of PBS, Enz, GB4-BPL@siCXCR2/pPTEN and Enz+GB4-BPL@siCXCR2/pPTEN in RM-1 EnzR tumor-bearing male C57BL/6J. Mice were castrated when the tumor volume reached 20-30 mm³ and received injections and oral gavage 3 days later. Injections were performed every 3 days for 5 times. Oral gavage was performed each day for 2 weeks. (B) Individual growth curves for mice treated as indicated (n = 6). (C) Tumor growth measurements show the in vivo therapeutic efficacy (n = 6). (D) Body weight of mice growth curves of the 4 groups (n = 6). (E) Tumor growth index at the end time points from each treatment (n = 6). (F) The microCT images of two groups in 2D and 3D (n = 4, red arrows: bone damaged sites). (G) The BMD values of the BmCRPC-bearing tibias of two groups (n = 4). (H) Representative Trap staining images of tumor-bearing tibias. (I) Representative OPG staining images of tumor-bearing tibias. (J) Representative BMP-2 staining images of tumor-bearing tibias. (scale bars = 20 μm). Data are represented as means ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: no significance, Student's t test and one-way ANOVA.